Press Release: Interfacebiologics : Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases

TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. ("IBI"), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce a positive pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases.